Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986148 alone and with nivolumab in advanced solid tumors
NCT02341625Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2015
- Primary completion
- Feb 2019
- Modality
- Antibody-Drug Conjugates (ADCs), Peptides, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label trial of BMS-986148 in mesothelioma, non-small cell lung cancer (NSCLC), ovarian cancer and 2 more (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events at Worst CTC Grade up to 6 months and Number of Participants With Laboratory Test Toxicity Grade Shifting From Baseline up to 6 months. Started Jun 2015; status: terminated.
02
Drugs
BMS-986148
03
Conditions
mesotheliomanon-small cell lung cancer (NSCLC)ovarian cancerpancreatic cancer (PC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT02341625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341625.